# IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

> **NCT03958383** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Wisconsin, Madison** · enrollment: 8 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** hu14.18-IL2
- **RADIATION:** Radiation Therapy
- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Ipilimumab

## Key facts

- **NCT ID:** NCT03958383
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-30
- **Primary completion:** 2024-01-06
- **Final completion:** 2026-08-15
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-04-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03958383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03958383, "IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT03958383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*